Global Celiac Disease Drug research
Global Celiac Disease Drug research

Celiac Disease Drug Comprehensive Study by Application (Hospitals, Clinics, Other), Distribution Channel (Over the Counter (OTC), Prescribed Medicine), Treatment Type (First-Line Treatment, Second-Line Treatment) Players and Region - Global Market Outlook to 2024

Celiac Disease Drug Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Sep 2019 Edition 250 Pages 167 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Celiac Disease Drug Market Scope
Celiac disease is an autoimmune disease in which the lining of the small intestine is damaged when the intake of gluten food is higher. This disease can lead to various health problems such as miscarriage or infertility, intestinal cancer, seizures, gall bladder malfunction, neurological manifestation of the disease, stunted growth in children, and birth defects.

The market study is being classified, by Application (Hospitals, Clinics and Other) and major geographies with country level break-up.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Celiac Disease Drug market throughout the predicted period.

F. Hoffmann-La Roche (Switzerland), Johnson & Johnson (United States), Merck (United States), Pfizer (United States), ADMA Biologics (United States), Amgen (United States), Anthera Pharmaceuticals (United States), Bayer (Germany), Biogen (United States), BioLineRx (Israel) and Biotest (Germany) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Bristol-Myers Squibb (United States), Celgene (United States), Takeda Pharmaceutical (Japan), Novartis (Switzerland), LFB Group (United States) and Kedrion Biopharma (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Celiac Disease Drug market by Type, Application and Region.

On the basis of geography, the market of Celiac Disease Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).


"Currently, there is no FDA-approved drug for the treatment of celiac disease. The only course of action available to celiac patients is to adhere to a strict, gluten-free diet, despite mounting evidence the diet alone is not enough for many of those suffering from ongoing symptoms and intestinal damage."

Market Trend
  • Research and Development in Healthcare Industry

Market Drivers
  • Increasing Awareness about the Healthcare Industry
  • An Upsurge in Disposable Income among the Population

Opportunities
  • Higher Consumption of Gluten-Containing Food
  • Ongoing Research on Celiac Disease Drug

Restraints
  • Drugs have a Side Effect on the Immune System

Challenges
  • Complex Regulation on These Drugs in Numerous Countries


Key Target Audience
Celiac Disease Drug Manufacturer, Celiac Disease Drug Supplier/Distributor, Raw Material Supplier, Government Bodies and Research Institutes

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Clinics
  • Other
By Distribution Channel
  • Over the Counter (OTC)
  • Prescribed Medicine

By Treatment Type
  • First-Line Treatment
  • Second-Line Treatment

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Awareness about the Healthcare Industry
      • 3.2.2. An Upsurge in Disposable Income among the Population
    • 3.3. Market Challenges
      • 3.3.1. Complex Regulation on These Drugs in Numerous Countries
    • 3.4. Market Trends
      • 3.4.1. Research and Development in Healthcare Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Celiac Disease Drug, by Application, Distribution Channel, Treatment Type and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Celiac Disease Drug (Value)
      • 5.2.1. Global Celiac Disease Drug by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Other
      • 5.2.2. Global Celiac Disease Drug by: Distribution Channel (Value)
        • 5.2.2.1. Over the Counter (OTC)
        • 5.2.2.2. Prescribed Medicine
      • 5.2.3. Global Celiac Disease Drug by: Treatment Type (Value)
        • 5.2.3.1. First-Line Treatment
        • 5.2.3.2. Second-Line Treatment
      • 5.2.4. Global Celiac Disease Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Celiac Disease Drug (Volume)
      • 5.3.1. Global Celiac Disease Drug by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Clinics
        • 5.3.1.3. Other
      • 5.3.2. Global Celiac Disease Drug by: Distribution Channel (Volume)
        • 5.3.2.1. Over the Counter (OTC)
        • 5.3.2.2. Prescribed Medicine
      • 5.3.3. Global Celiac Disease Drug by: Treatment Type (Volume)
        • 5.3.3.1. First-Line Treatment
        • 5.3.3.2. Second-Line Treatment
      • 5.3.4. Global Celiac Disease Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Celiac Disease Drug (Price)
  • 6. Celiac Disease Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ADMA Biologics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Anthera Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biogen (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BioLineRx (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Biotest (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Celiac Disease Drug Sale, by Application, Distribution Channel, Treatment Type and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Celiac Disease Drug (Value)
      • 7.2.1. Global Celiac Disease Drug by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Other
      • 7.2.2. Global Celiac Disease Drug by: Distribution Channel (Value)
        • 7.2.2.1. Over the Counter (OTC)
        • 7.2.2.2. Prescribed Medicine
      • 7.2.3. Global Celiac Disease Drug by: Treatment Type (Value)
        • 7.2.3.1. First-Line Treatment
        • 7.2.3.2. Second-Line Treatment
      • 7.2.4. Global Celiac Disease Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Celiac Disease Drug (Volume)
      • 7.3.1. Global Celiac Disease Drug by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Clinics
        • 7.3.1.3. Other
      • 7.3.2. Global Celiac Disease Drug by: Distribution Channel (Volume)
        • 7.3.2.1. Over the Counter (OTC)
        • 7.3.2.2. Prescribed Medicine
      • 7.3.3. Global Celiac Disease Drug by: Treatment Type (Volume)
        • 7.3.3.1. First-Line Treatment
        • 7.3.3.2. Second-Line Treatment
      • 7.3.4. Global Celiac Disease Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Celiac Disease Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Celiac Disease Drug: by Application(USD Million)
  • Table 2. Celiac Disease Drug Hospitals , by Region USD Million (2013-2018)
  • Table 3. Celiac Disease Drug Clinics , by Region USD Million (2013-2018)
  • Table 4. Celiac Disease Drug Other , by Region USD Million (2013-2018)
  • Table 5. Celiac Disease Drug: by Distribution Channel(USD Million)
  • Table 6. Celiac Disease Drug Over the Counter (OTC) , by Region USD Million (2013-2018)
  • Table 7. Celiac Disease Drug Prescribed Medicine , by Region USD Million (2013-2018)
  • Table 8. Celiac Disease Drug: by Treatment Type(USD Million)
  • Table 9. Celiac Disease Drug First-Line Treatment , by Region USD Million (2013-2018)
  • Table 10. Celiac Disease Drug Second-Line Treatment , by Region USD Million (2013-2018)
  • Table 11. South America Celiac Disease Drug, by Country USD Million (2013-2018)
  • Table 12. South America Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 13. South America Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 14. South America Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 15. Brazil Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 16. Brazil Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 17. Brazil Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 18. Argentina Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 19. Argentina Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 20. Argentina Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 21. Rest of South America Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 22. Rest of South America Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 23. Rest of South America Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 24. Asia Pacific Celiac Disease Drug, by Country USD Million (2013-2018)
  • Table 25. Asia Pacific Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 26. Asia Pacific Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 27. Asia Pacific Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 28. China Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 29. China Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 30. China Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 31. Japan Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 32. Japan Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 33. Japan Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 34. India Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 35. India Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 36. India Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 37. South Korea Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 38. South Korea Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 39. South Korea Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 40. Taiwan Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 41. Taiwan Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 42. Taiwan Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 43. Australia Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 44. Australia Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 45. Australia Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 46. Rest of Asia-Pacific Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 47. Rest of Asia-Pacific Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 49. Europe Celiac Disease Drug, by Country USD Million (2013-2018)
  • Table 50. Europe Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 51. Europe Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 52. Europe Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 53. Germany Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 54. Germany Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 55. Germany Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 56. France Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 57. France Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 58. France Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 59. Italy Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 60. Italy Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 61. Italy Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 62. United Kingdom Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 63. United Kingdom Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 64. United Kingdom Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 65. Netherlands Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 66. Netherlands Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 67. Netherlands Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 68. Rest of Europe Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 69. Rest of Europe Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 70. Rest of Europe Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 71. MEA Celiac Disease Drug, by Country USD Million (2013-2018)
  • Table 72. MEA Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 73. MEA Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 74. MEA Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 75. Middle East Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 76. Middle East Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 77. Middle East Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 78. Africa Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 79. Africa Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 80. Africa Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 81. North America Celiac Disease Drug, by Country USD Million (2013-2018)
  • Table 82. North America Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 83. North America Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 84. North America Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 85. United States Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 86. United States Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 87. United States Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 88. Canada Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 89. Canada Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 90. Canada Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 91. Mexico Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 92. Mexico Celiac Disease Drug, by Distribution Channel USD Million (2013-2018)
  • Table 93. Mexico Celiac Disease Drug, by Treatment Type USD Million (2013-2018)
  • Table 94. Celiac Disease Drug Sales: by Application(N)
  • Table 95. Celiac Disease Drug Sales Hospitals , by Region N (2013-2018)
  • Table 96. Celiac Disease Drug Sales Clinics , by Region N (2013-2018)
  • Table 97. Celiac Disease Drug Sales Other , by Region N (2013-2018)
  • Table 98. Celiac Disease Drug Sales: by Distribution Channel(N)
  • Table 99. Celiac Disease Drug Sales Over the Counter (OTC) , by Region N (2013-2018)
  • Table 100. Celiac Disease Drug Sales Prescribed Medicine , by Region N (2013-2018)
  • Table 101. Celiac Disease Drug Sales: by Treatment Type(N)
  • Table 102. Celiac Disease Drug Sales First-Line Treatment , by Region N (2013-2018)
  • Table 103. Celiac Disease Drug Sales Second-Line Treatment , by Region N (2013-2018)
  • Table 104. South America Celiac Disease Drug Sales, by Country N (2013-2018)
  • Table 105. South America Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 106. South America Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 107. South America Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 108. Brazil Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 109. Brazil Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 110. Brazil Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 111. Argentina Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 112. Argentina Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 113. Argentina Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 114. Rest of South America Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 115. Rest of South America Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 116. Rest of South America Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 117. Asia Pacific Celiac Disease Drug Sales, by Country N (2013-2018)
  • Table 118. Asia Pacific Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 119. Asia Pacific Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 120. Asia Pacific Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 121. China Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 122. China Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 123. China Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 124. Japan Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 125. Japan Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 126. Japan Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 127. India Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 128. India Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 129. India Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 130. South Korea Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 131. South Korea Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 132. South Korea Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 133. Taiwan Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 134. Taiwan Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 135. Taiwan Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 136. Australia Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 137. Australia Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 138. Australia Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 139. Rest of Asia-Pacific Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 140. Rest of Asia-Pacific Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 141. Rest of Asia-Pacific Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 142. Europe Celiac Disease Drug Sales, by Country N (2013-2018)
  • Table 143. Europe Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 144. Europe Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 145. Europe Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 146. Germany Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 147. Germany Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 148. Germany Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 149. France Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 150. France Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 151. France Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 152. Italy Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 153. Italy Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 154. Italy Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 155. United Kingdom Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 156. United Kingdom Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 157. United Kingdom Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 158. Netherlands Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 159. Netherlands Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 160. Netherlands Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 161. Rest of Europe Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 162. Rest of Europe Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 163. Rest of Europe Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 164. MEA Celiac Disease Drug Sales, by Country N (2013-2018)
  • Table 165. MEA Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 166. MEA Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 167. MEA Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 168. Middle East Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 169. Middle East Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 170. Middle East Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 171. Africa Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 172. Africa Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 173. Africa Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 174. North America Celiac Disease Drug Sales, by Country N (2013-2018)
  • Table 175. North America Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 176. North America Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 177. North America Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 178. United States Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 179. United States Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 180. United States Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 181. Canada Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 182. Canada Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 183. Canada Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 184. Mexico Celiac Disease Drug Sales, by Application N (2013-2018)
  • Table 185. Mexico Celiac Disease Drug Sales, by Distribution Channel N (2013-2018)
  • Table 186. Mexico Celiac Disease Drug Sales, by Treatment Type N (2013-2018)
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Celiac Disease Drug: by Application(USD Million)
  • Table 199. Celiac Disease Drug Hospitals , by Region USD Million (2019-2024)
  • Table 200. Celiac Disease Drug Clinics , by Region USD Million (2019-2024)
  • Table 201. Celiac Disease Drug Other , by Region USD Million (2019-2024)
  • Table 202. Celiac Disease Drug: by Distribution Channel(USD Million)
  • Table 203. Celiac Disease Drug Over the Counter (OTC) , by Region USD Million (2019-2024)
  • Table 204. Celiac Disease Drug Prescribed Medicine , by Region USD Million (2019-2024)
  • Table 205. Celiac Disease Drug: by Treatment Type(USD Million)
  • Table 206. Celiac Disease Drug First-Line Treatment , by Region USD Million (2019-2024)
  • Table 207. Celiac Disease Drug Second-Line Treatment , by Region USD Million (2019-2024)
  • Table 208. South America Celiac Disease Drug, by Country USD Million (2019-2024)
  • Table 209. South America Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 210. South America Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 211. South America Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 212. Brazil Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 213. Brazil Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 214. Brazil Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 215. Argentina Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 216. Argentina Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 217. Argentina Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 218. Rest of South America Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 219. Rest of South America Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 220. Rest of South America Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 221. Asia Pacific Celiac Disease Drug, by Country USD Million (2019-2024)
  • Table 222. Asia Pacific Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 223. Asia Pacific Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 224. Asia Pacific Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 225. China Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 226. China Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 227. China Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 228. Japan Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 229. Japan Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 230. Japan Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 231. India Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 232. India Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 233. India Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 234. South Korea Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 235. South Korea Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 236. South Korea Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 237. Taiwan Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 238. Taiwan Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 239. Taiwan Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 240. Australia Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 241. Australia Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 242. Australia Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 243. Rest of Asia-Pacific Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 244. Rest of Asia-Pacific Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 245. Rest of Asia-Pacific Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 246. Europe Celiac Disease Drug, by Country USD Million (2019-2024)
  • Table 247. Europe Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 248. Europe Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 249. Europe Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 250. Germany Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 251. Germany Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 252. Germany Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 253. France Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 254. France Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 255. France Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 256. Italy Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 257. Italy Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 258. Italy Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 259. United Kingdom Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 260. United Kingdom Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 261. United Kingdom Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 262. Netherlands Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 263. Netherlands Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 264. Netherlands Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 265. Rest of Europe Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 266. Rest of Europe Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 267. Rest of Europe Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 268. MEA Celiac Disease Drug, by Country USD Million (2019-2024)
  • Table 269. MEA Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 270. MEA Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 271. MEA Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 272. Middle East Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 273. Middle East Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 274. Middle East Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 275. Africa Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 276. Africa Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 277. Africa Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 278. North America Celiac Disease Drug, by Country USD Million (2019-2024)
  • Table 279. North America Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 280. North America Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 281. North America Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 282. United States Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 283. United States Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 284. United States Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 285. Canada Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 286. Canada Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 287. Canada Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 288. Mexico Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 289. Mexico Celiac Disease Drug, by Distribution Channel USD Million (2019-2024)
  • Table 290. Mexico Celiac Disease Drug, by Treatment Type USD Million (2019-2024)
  • Table 291. Celiac Disease Drug Sales: by Application(N)
  • Table 292. Celiac Disease Drug Sales Hospitals , by Region N (2019-2024)
  • Table 293. Celiac Disease Drug Sales Clinics , by Region N (2019-2024)
  • Table 294. Celiac Disease Drug Sales Other , by Region N (2019-2024)
  • Table 295. Celiac Disease Drug Sales: by Distribution Channel(N)
  • Table 296. Celiac Disease Drug Sales Over the Counter (OTC) , by Region N (2019-2024)
  • Table 297. Celiac Disease Drug Sales Prescribed Medicine , by Region N (2019-2024)
  • Table 298. Celiac Disease Drug Sales: by Treatment Type(N)
  • Table 299. Celiac Disease Drug Sales First-Line Treatment , by Region N (2019-2024)
  • Table 300. Celiac Disease Drug Sales Second-Line Treatment , by Region N (2019-2024)
  • Table 301. South America Celiac Disease Drug Sales, by Country N (2019-2024)
  • Table 302. South America Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 303. South America Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 304. South America Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 305. Brazil Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 306. Brazil Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 307. Brazil Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 308. Argentina Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 309. Argentina Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 310. Argentina Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 311. Rest of South America Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 312. Rest of South America Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 313. Rest of South America Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 314. Asia Pacific Celiac Disease Drug Sales, by Country N (2019-2024)
  • Table 315. Asia Pacific Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 316. Asia Pacific Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 317. Asia Pacific Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 318. China Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 319. China Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 320. China Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 321. Japan Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 322. Japan Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 323. Japan Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 324. India Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 325. India Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 326. India Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 327. South Korea Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 328. South Korea Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 329. South Korea Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 330. Taiwan Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 331. Taiwan Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 332. Taiwan Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 333. Australia Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 334. Australia Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 335. Australia Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 336. Rest of Asia-Pacific Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 337. Rest of Asia-Pacific Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 338. Rest of Asia-Pacific Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 339. Europe Celiac Disease Drug Sales, by Country N (2019-2024)
  • Table 340. Europe Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 341. Europe Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 342. Europe Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 343. Germany Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 344. Germany Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 345. Germany Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 346. France Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 347. France Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 348. France Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 349. Italy Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 350. Italy Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 351. Italy Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 352. United Kingdom Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 353. United Kingdom Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 354. United Kingdom Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 355. Netherlands Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 356. Netherlands Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 357. Netherlands Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 358. Rest of Europe Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 359. Rest of Europe Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 360. Rest of Europe Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 361. MEA Celiac Disease Drug Sales, by Country N (2019-2024)
  • Table 362. MEA Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 363. MEA Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 364. MEA Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 365. Middle East Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 366. Middle East Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 367. Middle East Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 368. Africa Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 369. Africa Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 370. Africa Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 371. North America Celiac Disease Drug Sales, by Country N (2019-2024)
  • Table 372. North America Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 373. North America Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 374. North America Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 375. United States Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 376. United States Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 377. United States Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 378. Canada Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 379. Canada Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 380. Canada Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 381. Mexico Celiac Disease Drug Sales, by Application N (2019-2024)
  • Table 382. Mexico Celiac Disease Drug Sales, by Distribution Channel N (2019-2024)
  • Table 383. Mexico Celiac Disease Drug Sales, by Treatment Type N (2019-2024)
  • Table 384. Research Programs/Design for This Report
  • Table 385. Key Data Information from Secondary Sources
  • Table 386. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Celiac Disease Drug: by Application USD Million (2013-2018)
  • Figure 5. Global Celiac Disease Drug: by Distribution Channel USD Million (2013-2018)
  • Figure 6. Global Celiac Disease Drug: by Treatment Type USD Million (2013-2018)
  • Figure 7. South America Celiac Disease Drug Share (%), by Country
  • Figure 8. Asia Pacific Celiac Disease Drug Share (%), by Country
  • Figure 9. Europe Celiac Disease Drug Share (%), by Country
  • Figure 10. MEA Celiac Disease Drug Share (%), by Country
  • Figure 11. North America Celiac Disease Drug Share (%), by Country
  • Figure 12. Global Celiac Disease Drug: by Application N (2013-2018)
  • Figure 13. Global Celiac Disease Drug: by Distribution Channel N (2013-2018)
  • Figure 14. Global Celiac Disease Drug: by Treatment Type N (2013-2018)
  • Figure 15. South America Celiac Disease Drug Share (%), by Country
  • Figure 16. Asia Pacific Celiac Disease Drug Share (%), by Country
  • Figure 17. Europe Celiac Disease Drug Share (%), by Country
  • Figure 18. MEA Celiac Disease Drug Share (%), by Country
  • Figure 19. North America Celiac Disease Drug Share (%), by Country
  • Figure 20. Global Celiac Disease Drug share by Players 2018 (%)
  • Figure 21. Global Celiac Disease Drug share by Players (Top 3) 2018(%)
  • Figure 22. Global Celiac Disease Drug share by Players (Top 5) 2018(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2018
  • Figure 26. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 27. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 28. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 29. Merck (United States) Revenue: by Geography 2018
  • Figure 30. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer (United States) Revenue: by Geography 2018
  • Figure 32. ADMA Biologics (United States) Revenue, Net Income and Gross profit
  • Figure 33. ADMA Biologics (United States) Revenue: by Geography 2018
  • Figure 34. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 35. Amgen (United States) Revenue: by Geography 2018
  • Figure 36. Anthera Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 37. Anthera Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 38. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 39. Bayer (Germany) Revenue: by Geography 2018
  • Figure 40. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 41. Biogen (United States) Revenue: by Geography 2018
  • Figure 42. BioLineRx (Israel) Revenue, Net Income and Gross profit
  • Figure 43. BioLineRx (Israel) Revenue: by Geography 2018
  • Figure 44. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 45. Biotest (Germany) Revenue: by Geography 2018
  • Figure 46. Global Celiac Disease Drug: by Application USD Million (2019-2024)
  • Figure 47. Global Celiac Disease Drug: by Distribution Channel USD Million (2019-2024)
  • Figure 48. Global Celiac Disease Drug: by Treatment Type USD Million (2019-2024)
  • Figure 49. South America Celiac Disease Drug Share (%), by Country
  • Figure 50. Asia Pacific Celiac Disease Drug Share (%), by Country
  • Figure 51. Europe Celiac Disease Drug Share (%), by Country
  • Figure 52. MEA Celiac Disease Drug Share (%), by Country
  • Figure 53. North America Celiac Disease Drug Share (%), by Country
  • Figure 54. Global Celiac Disease Drug: by Application N (2019-2024)
  • Figure 55. Global Celiac Disease Drug: by Distribution Channel N (2019-2024)
  • Figure 56. Global Celiac Disease Drug: by Treatment Type N (2019-2024)
  • Figure 57. South America Celiac Disease Drug Share (%), by Country
  • Figure 58. Asia Pacific Celiac Disease Drug Share (%), by Country
  • Figure 59. Europe Celiac Disease Drug Share (%), by Country
  • Figure 60. MEA Celiac Disease Drug Share (%), by Country
  • Figure 61. North America Celiac Disease Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • F. Hoffmann-La Roche (Switzerland)
  • Johnson & Johnson (United States)
  • Merck (United States)
  • Pfizer (United States)
  • ADMA Biologics (United States)
  • Amgen (United States)
  • Anthera Pharmaceuticals (United States)
  • Bayer (Germany)
  • Biogen (United States)
  • BioLineRx (Israel)
  • Biotest (Germany)
Additional players considered in the study are as follows:
Bristol-Myers Squibb (United States) , Celgene (United States) , Takeda Pharmaceutical (Japan) , Novartis (Switzerland) , LFB Group (United States) , Kedrion Biopharma (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation